Cargando…
Prevention of photosensitivity with action spectrum adjusted protection for erythropoietic protoporphyria
Erythropoietic protoporphyria is a genetic disease characterized by sensitivity to sunlight caused by the accumulation of protoporphyrin IX. Photoprotection against ultraviolet A and visible light is necessary for erythropoietic porphyria patients because the absorption spectrum of protoporphyrin IX...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814858/ https://www.ncbi.nlm.nih.gov/pubmed/29266358 http://dx.doi.org/10.1111/1346-8138.14175 |
_version_ | 1783300415604916224 |
---|---|
author | Teramura, Takashi Mizuno, Makoto Asano, Hajime Naru, Eiji Kawara, Shigeru Kamide, Ryoichi Kawada, Akira |
author_facet | Teramura, Takashi Mizuno, Makoto Asano, Hajime Naru, Eiji Kawara, Shigeru Kamide, Ryoichi Kawada, Akira |
author_sort | Teramura, Takashi |
collection | PubMed |
description | Erythropoietic protoporphyria is a genetic disease characterized by sensitivity to sunlight caused by the accumulation of protoporphyrin IX. Photoprotection against ultraviolet A and visible light is necessary for erythropoietic porphyria patients because the absorption spectrum of protoporphyrin IX lies in both ultraviolet A and visible light region. We developed a novel index, in vitro porphyrin protection factor, based on the protoporphyrin IX absorbance spectrum. We also selected appropriate photoprotective products designed according to protoporphyrin IX absorbance. The porphyrin protection factors of a combination of make‐up base with a powder as well as with a liquid foundation were significantly higher than those of a conventional sunscreen product, even at a small application dose. An in‐use test carried out for 6 months showed that the efficacy of these products was 78.3%, and no adverse reactions were observed. Male subjects preferred liquid foundation, whereas all female subjects used powder foundation. The preference of the subjects could lead to the long‐term use of the tested products. In conclusion, this study provided a new approach to improve photoprotection in erythropoietic protoporphyria patients. |
format | Online Article Text |
id | pubmed-5814858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58148582018-02-27 Prevention of photosensitivity with action spectrum adjusted protection for erythropoietic protoporphyria Teramura, Takashi Mizuno, Makoto Asano, Hajime Naru, Eiji Kawara, Shigeru Kamide, Ryoichi Kawada, Akira J Dermatol Original Articles Erythropoietic protoporphyria is a genetic disease characterized by sensitivity to sunlight caused by the accumulation of protoporphyrin IX. Photoprotection against ultraviolet A and visible light is necessary for erythropoietic porphyria patients because the absorption spectrum of protoporphyrin IX lies in both ultraviolet A and visible light region. We developed a novel index, in vitro porphyrin protection factor, based on the protoporphyrin IX absorbance spectrum. We also selected appropriate photoprotective products designed according to protoporphyrin IX absorbance. The porphyrin protection factors of a combination of make‐up base with a powder as well as with a liquid foundation were significantly higher than those of a conventional sunscreen product, even at a small application dose. An in‐use test carried out for 6 months showed that the efficacy of these products was 78.3%, and no adverse reactions were observed. Male subjects preferred liquid foundation, whereas all female subjects used powder foundation. The preference of the subjects could lead to the long‐term use of the tested products. In conclusion, this study provided a new approach to improve photoprotection in erythropoietic protoporphyria patients. John Wiley and Sons Inc. 2017-12-20 2018-02 /pmc/articles/PMC5814858/ /pubmed/29266358 http://dx.doi.org/10.1111/1346-8138.14175 Text en © 2017 KOSÉ Corporation. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Teramura, Takashi Mizuno, Makoto Asano, Hajime Naru, Eiji Kawara, Shigeru Kamide, Ryoichi Kawada, Akira Prevention of photosensitivity with action spectrum adjusted protection for erythropoietic protoporphyria |
title | Prevention of photosensitivity with action spectrum adjusted protection for erythropoietic protoporphyria |
title_full | Prevention of photosensitivity with action spectrum adjusted protection for erythropoietic protoporphyria |
title_fullStr | Prevention of photosensitivity with action spectrum adjusted protection for erythropoietic protoporphyria |
title_full_unstemmed | Prevention of photosensitivity with action spectrum adjusted protection for erythropoietic protoporphyria |
title_short | Prevention of photosensitivity with action spectrum adjusted protection for erythropoietic protoporphyria |
title_sort | prevention of photosensitivity with action spectrum adjusted protection for erythropoietic protoporphyria |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814858/ https://www.ncbi.nlm.nih.gov/pubmed/29266358 http://dx.doi.org/10.1111/1346-8138.14175 |
work_keys_str_mv | AT teramuratakashi preventionofphotosensitivitywithactionspectrumadjustedprotectionforerythropoieticprotoporphyria AT mizunomakoto preventionofphotosensitivitywithactionspectrumadjustedprotectionforerythropoieticprotoporphyria AT asanohajime preventionofphotosensitivitywithactionspectrumadjustedprotectionforerythropoieticprotoporphyria AT narueiji preventionofphotosensitivitywithactionspectrumadjustedprotectionforerythropoieticprotoporphyria AT kawarashigeru preventionofphotosensitivitywithactionspectrumadjustedprotectionforerythropoieticprotoporphyria AT kamideryoichi preventionofphotosensitivitywithactionspectrumadjustedprotectionforerythropoieticprotoporphyria AT kawadaakira preventionofphotosensitivitywithactionspectrumadjustedprotectionforerythropoieticprotoporphyria |